Monitor Cosmos for the next quarterly filing (10-Q) detailing R&D expense associated with the nanotechnology initiative and any patent-office updates. Without disclosed deal economics or revenue guidance, this filing does not alter near-term financial projections.
Price Chart
Executive Summary
Cosmos Health's subsidiary Cana Laboratories acquired international patent application WO2025108566A1 from Cloudpharm P.C. and plans expanded nanotechnology investments. The deal adds early-stage IP to Cosmos's portfolio but lacks disclosed financial terms, FDA catalyst, or near-term revenue impact — making it an early-stage R&D step with limited immediate valuation effect.
Key Facts
- Cana Laboratories acquired patent application WO2025108566A1 from Cloudpharm P.C.
- Patent protection being pursued at national/regional levels across key international markets.
- Technology targets pharma, nutraceutical, OTC, and specialized healthcare products.
- Cana Laboratories is European GMP-licensed and EMA-certified.
- No financial terms (deal value, upfront, milestones) disclosed.
- No revenue contribution or commercial launch timeline provided.
Financial Impact
Undisclosed — no consideration, milestones, or revenue projections provided in the release.
Risk Factors
- Patents remain at application stage — no guarantee of grant or commercial viability.
- No disclosed cash outflow or financing commitment could create future dilution if R&D spend escalates.
- Micro-cap liquidity ($15M market cap) amplifies downside if IP fails to monetize.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3308237 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.2530 | awaiting T+20 | — | $0.2386 (−5.69%) |
Oct 16, 2026 10d ago | SC 13G/A | $0.3250 | awaiting T+20 | — | $0.2386 (−26.58%) |
Oct 9, 2026 17d ago | 8-K | $0.3496 | awaiting T+20 | — | $0.2386 (−31.75%) |
Sep 3, 2026 7w ago | Press Release | $0.2660 $0.4300 | ▼ −61.65% | ▼ −62.77% | $0.2386 (+10.30%) |
Aug 19, 2026 9w ago | Press Release | $0.1930 | awaiting T+20 | — | $0.2386 (−23.63%) |
Jul 20, 2026 14w ago | Press Release | $0.2303 $0.2050 | ▼ −10.99% | ▼ −15.11% | $0.2386 (+3.60%) |
Jul 17, 2026 14w ago | Press Release | $0.2348 $0.2179 | ▼ −7.20% | ▼ −11.64% | $0.2386 (+1.62%) |
Jul 16, 2026 14w ago | Press Release | $0.2807 $0.2065 | ▼ −26.43% | ▼ −30.05% | $0.2386 (−15.00%) |
Jul 15, 2026 14w ago | Press Release | $0.2785 $0.2071 | ▼ −25.64% | ▼ −27.98% | $0.2386 (−14.33%) |
Jul 14, 2026 14w ago | Press Release | $0.3071 $0.2198 | ▼ −28.43% | ▼ −30.92% | $0.2386 (−22.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers